Diabetes, hypertension, and aging are major contributors to cardiovascular and chronic
kidney disease (CKD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors have become a …

Gliflozins (sodium-glucose transporter-2 inhibitors) exhibited renoprotective effects not only
in diabetic but also in non-diabetic patients with chronic kidney disease (CKD) …

Diabetic nephropathy is the leading cause of end-stage renal disease in humans in the
Western world. The recent development of Na+-glucose cotransporter 2 (SGLT2) inhibitors …

Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors are widely used to reduce
hyperglycemia. The present study investigated the effects of a SGLT2 inhibitor …

The new antidiabetic drugs, gliflozins, inhibit sodium-glucose transporter-2 in renal proximal
tubules promoting glucose and sodium excretion. This leads not only to a significant …

Our previous work has shown that gene knockout of the sodium-glucose cotransporter
SGLT2 modestly lowered blood glucose in streptozotocin-diabetic mice (BG; from 470 to 300 …

Introduction Empagliflozin, a known inhibitor of sodium-glucose cotransporter type 2
(SGLT2) decreases glucose reabsorption by the renal tubules and promotes glucose …

Objective: Hypertension and Diabetes commonly coexist and have been implicated in
deterioration of kidneys, heart and impairment of pancreas. Empagliflozin (Empa), a …

Blood glucose control is the primary strategy to prevent complications in diabetes. At the
onset of kidney disease, therapies that inhibit components of the renin angiotensin system …

Impaired pressure natriuresis (PN) underlies salt-sensitive hypertension, and renal
inflammation and hypoxia-inducible factor-1 (HIF-1) have been implicated in the modulation …